RNAi Leadership Position Alnylam as a leader in RNA interference therapeutics with a track record of six approved medicines and ongoing development across rare and prevalent diseases, highlighting a proven pipeline for partnering or co-development in genetic and cardiovascular indications.

Financial Momentum Leverage the strong revenue trajectory with quarterly product revenue surpassing one billion dollars for Q1 2026, signaling growing market adoption and potential for scaled manufacturing partnerships, payer strategies, and international expansion opportunities.

Global Footprint Target multinational health systems and CROs leveraging Alnylam’s global presence, diverse offices, and scalable operations to propose collaborative trials, regional manufacturing, and market access initiatives across North America, Europe, Asia, and South America.

Strategic Partnerships Explore BD opportunities around supplementary technologies and services (data analytics, supply chain, digital patient engagement) given their tech stack and SAP Ariba, Webex, Tableau usage, enabling integrated solutions for regulatory, manufacturing, and commercialization needs.

Risk & Compliance Acknowledge ongoing regulatory and securities scrutiny signals in recent news; proactively offer transparent governance, due diligence support, and investor communications services to reassure stakeholders while pursuing strategic collaborations.